Treats Attention-Deficit/Hyperactivity Disorder (ADHD). ANDA 79017, held by Zydus Pharms USA Inc. Atomoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 79017 (Atomoxetine Hydrochloride), held by Zydus Pharms USA Inc, was first approved by FDA on Sep 16, 2010, with 3 approved supplements and 0 published complete response letters.
Atomoxetine is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). 1.1 Attention-Deficit/Hyperactivity Disorder (ADHD)
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 16, 2010 | Original application | Approved | None posted |
| Atomoxetine HydrochlorideEQ 18MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 25MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 40MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 60MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 80MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 100MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 10MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Aug 25, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 25, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 7, 2013 | Supplement 2Labeling | Approved | None posted |
| Sep 16, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters